RecruitingPhase 3NCT04031677
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Studying Leiomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Intervention
- Surgery(procedure)
- Enrollment
- 250 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UCI Health-Chao Family Comp CC and Ambulatory Care, Irvine, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- UC Irvine Health/Chao Family Comprehensive Ca Ctr, Orange, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut, United States
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut, United States
- Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States
- Smilow Cancer Hospital Care Ctr at Saint Francis, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Canadian Cancer Trials Group · ECOG-ACRIN Cancer Research Group · Anticancer Fund, Belgium · Australia and New Zealand Sarcoma Association · Japan Clinical Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04031677 on ClinicalTrials.govOther trials for Leiomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07125183Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaUniversity of Colorado, Denver
- ENROLLING BY INVITATIONNANCT07405346A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized EfficacyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT06957431Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaWashington University School of Medicine
- RECRUITINGPHASE2NCT07076186Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT06528769Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaGabriel Tinoco
- RECRUITINGPHASE2NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourUNICANCER
- RECRUITINGPHASE2NCT06571734XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable LeiomyosarcomaNorthwestern University
- RECRUITINGPHASE1NCT06308419A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsM.D. Anderson Cancer Center